miR-182 regulates trastuzumab resistance by targeting MET in breast cancer cells.

Published on Feb 1, 2019in Cancer Gene Therapy4.534
· DOI :10.1038/S41417-018-0031-4
Dan Yue1
Estimated H-index: 1
(PRC: China Medical University (PRC)),
Xiaosong Qin1
Estimated H-index: 1
(PRC: China Medical University (PRC))
Sources
Abstract
It has been found that microRNAs (miRNAs) play a key role in drug resistance. The purpose of the current study was to investigate the function of miR-182 in trastuzumab resistance in breast cancer cells. The results showed that both breast cancer SKBR3 trastuzumab-resistant cells (SKBR3/TR) and BT474 trastuzumab-resistant cells (BT474/TR) were associated with miR-182 downregulation compared with their parental cells. Ectopic expression of the miR-182 mimic inhibited trastuzumab resistance, decreasing the invasion and migration of these trastuzumab-resistant cells. However, the miR-182 inhibitor increased trastuzumab resistance, cell invasion, and migration in the parental cells. In addition, MET is a directly targeted gene of miR-182 in breast cancer cells. MET knockdown showed an inhibitory effect of trastuzumab resistance on trastuzumab-resistant cells. In contrast, MET overexpression in SKBR3 cells produced an effect that promotes resistance to trastuzumab. Moreover, we revealed that overexpression of miR-182 reduced trastuzumab resistance in trastuzumab-resistant cells due in part to MET/PI3K/AKT/mTOR signaling pathway inactivation. Furthermore, miR-182 could also sensitize SKBR3/TR cells to trastuzumab in vivo. In conclusion, our results suggest that the activation of miR-182 or inactivation of its target gene pathway could be used as a new method to reverse trastuzumab resistance in breast cancer.
📖 Papers frequently viewed together
7 Citations
8 Citations
20087.97Oncogene
7 Authors (Clodia Osipo, ..., Lucio Miele)
179 Citations
References34
Newest
#1Deepak Arya (Manipal University)H-Index: 3
#2Sasikala P. Sachithanandan (NCBS: National Centre for Biological Sciences)H-Index: 2
Last. Sudhir Krishna (NCBS: National Centre for Biological Sciences)H-Index: 21
view all 6 authors...
The deregulation of lineage control programs is often associated with the progression of haematological malignancies. The molecular regulators of lineage choices in the context of tyrosine kinase inhibitor (TKI) resistance remain poorly understood in chronic myeloid leukemia (CML). To find a potential molecular regulator contributing to lineage distribution and TKI resistance, we undertook an RNA-sequencing approach for identifying microRNAs (miRNAs). Following an unbiased screen, elevated miRNA...
8 CitationsSource
#1Elena Laakmann (UHH: University of Hamburg)H-Index: 7
#2Volkmar Müller (UHH: University of Hamburg)H-Index: 67
Last. Isabell Witzel (UHH: University of Hamburg)H-Index: 20
view all 4 authors...
Background: The incidence of brain metastases (BM) in breast cancer patients has increased. Many retrospective analyses have shown that first-line treatment with
15 CitationsSource
#1Ping Wee (U of A: University of Alberta)H-Index: 6
#2Zhixiang Wang (U of A: University of Alberta)H-Index: 30
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that is commonly upregulated in cancers such as in non-small-cell lung cancer, metastatic colorectal cancer, glioblastoma, head and neck cancer, pancreatic cancer, and breast cancer. Various mechanisms mediate the upregulation of EGFR activity, including common mutations and truncations to its extracellular domain, such as in the EGFRvIII truncations, as well as to its kinase domain, such as the L858R and T790M mutations, ...
449 CitationsSource
#1Giampaolo Bianchini (UniSR: Vita-Salute San Raffaele University)H-Index: 26
#2Justin M. Balko (VUMC: Vanderbilt University Medical Center)H-Index: 54
Last. Luca Gianni (UniSR: Vita-Salute San Raffaele University)H-Index: 85
view all 5 authors...
Triple-negative breast cancer has a poor outcome compared with other breast cancer subgroups, and chemotherapy is the primary treatment for this disease. 'Omics' technologies have revealed high levels of heterogeneity and helped to identify potentially actionable molecular features in some triple-negative breast cancer subtypes. Proof-of-principle studies suggest a potential benefit from immunotherapy in patients with this disease. Herein, Bianchini et al. discuss the most promising therapeutic ...
937 CitationsSource
#1Antonio Ieni (UNIME: University of Messina)H-Index: 21
#2Valeria Barresi (UNIME: University of Messina)H-Index: 27
Last. Giovanni Tuccari (UNIME: University of Messina)H-Index: 24
view all 6 authors...
4 CitationsSource
#1Chi-Hsiang Chiang (NHRI: National Health Research Institutes)H-Index: 4
#2Pei-Yi Chu (Memorial Hospital of South Bend)H-Index: 27
Last. Wen-Chun Hung (KMU: Kaohsiung Medical University)H-Index: 25
view all 4 authors...
The feature of imperfect complementary effect of miRNAs to mRNAs implies that miRNAs may simultaneously target different mRNAs to affect multiple aspects of tumorigenesis. In our previous results, we demonstrated that miR-182 was over-expressed in breast cancer cell lines and clinical tumor tissues and its up-regulation increased tumorigenicity and invasiveness by repressing a tumor suppressor RECK. In this study, we showed that overexpression miR-182 regulated actin distribution and filopodia f...
36 Citations
#1Joëlle CollignonH-Index: 10
#2Laurence LousbergH-Index: 3
Last. Guy JerusalemH-Index: 50
view all 4 authors...
Triple-negative breast cancers (TNBCs) are defined by the absence of estrogen and progesterone receptors and the absence of HER2 overexpression. These cancers represent a heterogeneous breast cancer subtype with a poor prognosis. Few systemic treatment options exist besides the use of chemotherapy (CT). The heterogeneity of the disease has limited the successful development of targeted therapy in unselected patient populations. Currently, there are no approved targeted therapies for TNBC. Howeve...
141 CitationsSource
#1Dong‑Lin Bian (PRC: China Medical University (PRC))H-Index: 1
#2Xuemei Wang (PRC: China Medical University (PRC))H-Index: 5
Last. Cheng‑Hua Wu (PRC: China Medical University (PRC))H-Index: 1
view all 6 authors...
The aim of the present study was to evaluate the expression level of microRNA-182 (miRNA-182) in human osteosarcoma (OS) MG-63 cells and OS tissues, and to elucidate the effect of miRNA-182 on the biological activity of tumors. In the present study, the expression of miRNA-182 in human OS MG-63 cells, OS tissues and normal osteoblast hFOB1.19 cells was determined using quantitative polymerase chain reaction. Subsequently, a miRNA-182 mimic and inhibitor were utilized to regulate the expression l...
7 CitationsSource
#1Maria Luque-CabalH-Index: 2
Last. Isabel Palacio-VázquezH-Index: 1
view all 5 authors...
The introduction of trastuzumab therapy markedly improved the poor prognosis associated with HER2-amplified breast cancers. Despite this, the presence of primary and acquired resistance to trastuzumab treatment remains a significant common challenge. The identification of resistance mechanisms and the incorporation of new drugs that achieve a better blockade of HER family receptors signaling have resulted in improved outcomes. The phosphatidylinositol 3’-kinase/protein kinase B/mammalian target ...
86 CitationsSource
#1Simon B. Zeichner (Emory University)H-Index: 12
#2Hiromi Terawaki (Emory University)H-Index: 2
Last. Keerthi Gogineni (Emory University)H-Index: 6
view all 3 authors...
Patients with breast cancer along with metastatic estrogen and progesterone receptor (ER/PR)- and human epidermal growth factor receptor 2 (HER2)-negative tumors are referred to as having metastatic triple-negative breast cancer (mTNBC) disease. Although there have been many new treatment options approved by the Food and Drug Administration for ER/PR-positive and Her2/neu-amplified metastatic breast cancer, relatively few new agents have been approved for patients with mTNBC. There have been sev...
97 CitationsSource
Cited By9
Newest
#1Erica Gentilin (UNIPD: University of Padua)H-Index: 2
#2Paolo Gandellini (University of Milan)H-Index: 25
Source
#1Nina Petrovic (University of Belgrade)H-Index: 9
#2Irina Nakashidze (Shota Rustaveli State University)H-Index: 2
Last. Milica NedeljkovićH-Index: 1
view all 3 authors...
Breast cancer (BC) is a leading cause of death among women with malignant diseases. The selection of adequate therapies for highly invasive and metastatic BCs still represents a major challenge. Novel combinatorial therapeutic approaches are urgently required to enhance the efficiency of BC treatment. Recently, microRNAs (miRNAs) emerged as key regulators of the complex mechanisms that govern BC therapeutic resistance and susceptibility. In the present review we aim to critically examine how miR...
2 CitationsSource
#1Rui Liu (Beijing University of Chinese Medicine)H-Index: 4
#2Youwen Chen (Beijing University of Chinese Medicine)H-Index: 3
Last. Yuanyan Liu (Beijing University of Chinese Medicine)H-Index: 14
view all 10 authors...
Multidrug resistance (MDR) is the dominant challenge in the failure of chemotherapy in cancers. Phosphatidylinositol 3-kinase (PI3K) is a lipid kinase that spreads intracellular signal cascades and regulates a variety of cellular processes. PI3Ks are considered significant causes of chemoresistance in cancer therapy. Protein kinase B (AKT) is also a significant downstream effecter of PI3K signaling, and it modulates several pathways, including inhibition of apoptosis, stimulation of cell growth,...
31 CitationsSource
#1Rao Fu (Electric Power University)H-Index: 1
#2Jing-Shan Tong (University of Pittsburgh)H-Index: 2
: MicroRNAs (miRNAs) have been found to play a key role in drug resistance. In the current study, we aimed to explore the potential role of miR-126 in trastuzumab resistance in breast cancer cells. We found that the trastuzumab-resistant cell lines SKBR3/TR and BT474/TR had low expression of miR-126 and increased ability to migrate and invade. The resistance, invasion and mobilization abilities of the cells resistant to trastuzumab were reduced by ectopic expression of miR-126 mimics. In compari...
7 CitationsSource
#1Dharambir Kashyap (PGIMER: Post Graduate Institute of Medical Education and Research)H-Index: 18
#2Harmandeep Kaur (St. Michael's Hospital)H-Index: 2
Abstract Breast cancer is one of the genetic diseases causing a high mortality among women around the world. Despite the availability of advanced diagnostic tools and treatment strategies, the incidence of breast cancer is increasing every year. This is due to the lack of accurate and reliable biomarkers whose deficiency creates difficulty in early breast cancer recognition, subtypes determination, and metastasis prophecy. Although biomarkers such as ER, PR, Her2, Ki-67, and other genetic platfo...
18 CitationsSource
#1Xin Liu (Zhengzhou University)H-Index: 7
#2Ranran Sun (Zhengzhou University)H-Index: 17
Last. Zujiang Yu (Zhengzhou University)H-Index: 17
view all 9 authors...
Several lines of evidence have confirmed the magnitude of crosstalk between HGF/c-Met axis (hepatocyte growth factor and its high-affinity receptor c-mesenchymal-epithelial transition factor) and non-coding RNAs (ncRNAs) in tumorigenesis. Through activating canonical or non-canonical signaling pathways, the HGF/c-Met axis mediates a range of oncogenic processes such as cell proliferation, invasion, apoptosis, and angiogenesis and is increasingly becoming a promising target for cancer therapy. Me...
5 CitationsSource
#1G. K. Rajanikant (NITC: National Institute of Technology Calicut)H-Index: 18
#1G. K. Rajanikant (NITC: National Institute of Technology Calicut)H-Index: 10
Last. Cindy Bokobza (University of Paris)H-Index: 3
view all 5 authors...
The past decade witnessed a paradigm shift of attention from a protein-centric approach to RNA centric approach in understanding the complexity of multi-factorial diseases like ischemic stroke. Thus, marking the beginning of a new class of non-protein-coding genes, exemplified by the intense research on microRNA, in human physiology and disease. However, microRNAs are just the beginning of a whole new world of non-coding RNAs (ncRNAs), with unexplored limitless functionalities. These ncRNAs are ...
Source
#1Fei Liu (Southern Medical University)H-Index: 2
#1Fei Liu (Southern Medical University)H-Index: 1
Last. Jinchun Xing (Ha Tai: Xiamen University)H-Index: 15
view all 5 authors...
Purpose Clear cell renal cell carcinoma (ccRCC) has the highest rate of metastasis and invasion in RCC and is the third most common adult urinary malignancy. miRNA may serve a critical role in human cancer development and progression, has been confirmed to play a pivotal role in RCC cell invasion and migration. Since miR‑935 had been verified to be an oncogene or tumor suppressor in various cancers, the role of miR‑935 in RCC was unclear.
7 CitationsSource
Trastuzumab represents the predominant therapy to target breast cancer subtype marked by HER2 amplification. It has been in use for two decades and its continued importance is underlined by recent FDA approvals of its biosimilar and conjugated versions. Progression to an aggressive disease with acquisition of resistance to trastuzumab remains a major clinical concern. In addition to a number of cellular signaling pathways being investigated, focus in recent years has also shifted to epigenetic a...
13 CitationsSource